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Abstract
A wide variety of non-surgical therapies can result in clinical responses in patients with hepatocellular carcinoma. Two recent
studies have suggested that transarterial chemoembolisation can, in highly selected patients with good liver function, result in
an improvement in survival. No other approaches have, to date, demonstrated convincing evidence of survival advantage.
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Introduction
Surgical resection is currently considered to be the
definitive treatment for hepatocellular carcinoma
(HCC) and the only one that offers the prospect of cure
or at least long-term survival. However, most patients
have unresectable disease at presentation because of
poor liver function (about 75% will have underlying
chronic liver disease), bilobar disease, invasion of
the major vessels or overt extrahepatic metastases. The
overall resectability rate for HCC is thus only 10–25%
and even among those who undergo surgical resection
with curative intent, there is a recurrence rate of up to
80% at 5 years [1–3]. More recently there have been
suggestions that other therapeutic modalities such as
percutaneous ethanol injection (PEI) and radio-
frequency ablation (RFA) are also potentially “cura-
tive”. It should be noted that the term “curative” in this
sense is usually meant to imply “resulting in complete
local control of the original lesion”. Cure in the strict
and true sense of the word is seldom achieved.
Where conventional surgical resection is contra-
indicated because of poor underlying liver function,
orthotopic liver transplantation is an option, particu-
larly for those who have small tumours [4–6] but again
recurrence remains a possibility and shortage of donor
livers means that many will succumb while awaiting
transplantation. It is thus apparent that the majority
of patients with HCC will, at some point during the
course of their disease, be candidates for non-surgical
therapy. It is also apparent that they represent, by
virtue of whatever factors preclude them for surgical
resection, a relatively poor risk group.
Non-surgical treatment can be classified as loco-
regional, including intra-arterial or percutaneous local
ablative approaches, a combination of the two, or
systemic. When regional lymph nodes are involved or
there are extrahepatic metastases, locoregional treat-
ment is seldom indicated. Intra-arterial treatment is
also contraindicated when there is involvement of
the main portal venous system. Systemic chemo-
therapy is usually considered for the patients who are
unsuitable for any of the above treatments.
It should be emphasized from the start that “liver
failure” as indicated by overt jaundice, recurrent or
diuretic-resistant ascites, recurrent gastrointestinal
haemorrhage or encephalopathy unexplained by other
factors will, in the view of most authorities, preclude
any form of active treatment other than liver trans-
plantation. In such patients prognosis is primarily
defined by the underlying liver function rather than the
tumour; effective anti-tumour therapy may not neces-
sarily improve overall survival. Figures will vary from
unit to unit and around the world but as a very broad
generalization 15% of patients will be considered for
surgical resection, 50% for non-surgical therapies and
35% will be unsuitable for any active treatment, and
will receive best supportive care. These figures will
change as more patients are detected in the asympto-
matic stage by screening.
Intra-arterial and regional drug delivery
With the disappointing results seen with systemic
therapy, several approaches that aim to target the
tumour specifically have been developed. There are
two ways in which targeting may be achieved. The first
approach is based on the observation that primary and
secondary liver tumours derive the bulk of their blood
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supply from the hepatic artery [7]. This approach to
selectivity may be further enhanced by new arterio-
graphic procedures that permit “super selective”
catheterization of the tumour-feeding artery. Direct
infusion of cytotoxic agents into the hepatic artery may
allow an increase of the exposure of the tumour to the
drug. Depending on the agent used, the time/con-
centration interval may increase by up to 400-fold.
Dose-limiting toxicity may then become “regional”
(i.e. hepatic and not systemic) [8–11].
A second source of selectivity is the use of lipiodol as
a vehicle for cytotoxic chemotherapy. This oily based
contrast medium, when injected into the hepatic artery
at the time of arteriography, is cleared from normal
hepatic tissues but accumulates in malignant tumours,
probably because of the leaky character of neovascular
tissue, combined with the lack of lymphatic clearance
from tumour tissue [12]. The lipiodol forms an emul-
sion with the cytotoxic agent and then acts as a reser-
voir for the prolonged delivery of the agent to the
tumour, and perhaps enhances uptake by the tumour
cells. The extent to which the lipiodol acts as an
embolizing agent in itself remains controversial.
There seems no doubt that, compared with systemic
administration [13–15], drugs given intra-arterially are
more effective, although it must not be forgotten that
patients treated in this manner invariably have a better
performance status than those treated with systemic
therapy. For this reason, better results would be
expected regardless of any inherent increased efficacy
of the treatment.
Transcatheter oily chemoembolization (TACE)
Following hepatic angiography to identify the arterial
anatomy and the blood supply of the tumour a catheter
is placed in the appropriate vessel. Not infrequently
angiography identifies tumour not detected by CT
scanning. In the past the entire liver has been covered
by placement of the catheter in the proper hepatic
artery but nowadays it is more common to use the left
or right hepatic artery when the whole of one lobe is
involved, or, where feasible, to selectively catheterize
just the tumour-feeding arteries, and the procedure
becomes “segmental”. The cytotoxic drug (usually
doxorubicin or cisplatin) is mixed with lipiodol and the
emulsion is injected slowly. Finally, embolization with
0.5–1 mm of gelatin cubes or a similar material is
undertaken [16].
The presence of Child’s grade C cirrhosis is usually
considered to be a contraindication, as is thrombosis of
the portal vein, because the cirrhotic liver is crucially
dependent on the hepatic artery in this situation, and
any further interruption thereof may lead to liver fail-
ure. Thrombosis of the portal vein is also an indication
of particularly bad prognosis and is associated with the
development of extrahepatic disease. If the procedure
is undertaken by an experienced interventional radio-
logist the mortality should be well below 5% and
significant side effects are rare (1%) apart from occa-
sional gallbladder infarction [17]. Effective embol-
ization is often associated with the so-called “post
embolization syndrome” of fever, pain and vomiting
for up to a week, after which it subsides spontaneously.
Significant deterioration in liver function may occur
but usually only when Child’s grade C patients are
treated. Although widely regarded as standard treat-
ment for almost 15 years, and clear evidence that
tumour necrosis was indeed caused, early controlled
trials did not show an increase in survival and the
consensus was that although the “primary effect” (i.e.
causing tumour volume reduction) is good, there is
little effect on long-term survival for which other
factors such as the tumour type, degree of spread and
serum alpha-fetoprotein (AFP) level are more signifi-
cant than the treatment [18–21].
However, more recently, two trials and a systematic
review have, for the first time, provided evidence
that TACE may indeed improve survival, in selected
cases. In the first of these Lo et al. randomized 80
subjects to either TACE (with cisplatin in lipiodol
followed by gelatin sponge embolization) or best
supportive therapy [22]. The survival figures at 1, 2
and 3 years were 57%, 31% and 26% compared with
32%, 11% and 3%, respectively (p=0.006). In the
second study, from Spain, 112 patients were rando-
mized to TACE with doxorubicin again followed by
gelfoam embolization, or best supportive therapy [23].
Survival figures at 1 and 2 years were 82% and 63% in
the TACE group compared with 75% and 50% for
embolization alone and 63% and 27% for those
receiving best supportive therapy. In both studies the
procedure was repeated if there was no evidence of
progressive disease. The systematic review suggested
that chemoembolization, either doxorubicin or cispla-
tin, but not embolization alone showed a significant
benefit (2-year probability of survival, compared with
control, odds ratio 0.53 with 95% confidence limits of
0.32–0.89). The systematic review again suggested
that benefits were mainly in those with well preserved
liver function (Child’s grade A) and without vascular
invasion [16].
While these two studies have, according to many
authorities, established TACE as the standard of care
for patients with larger HCCs, we should remain
cautious. Both trials were small, and some criticisms
about how well the treatment and control groups were
balanced have been raised. Furthermore, and of
particular importance in designing further comparative
studies, there remains considerable controversy as
to what is actually meant by the term “chemoem-
bolization” and the relative importance of the
“embolization” and the “chemotherapy” aspects of the
treatment. It is notable that different cytotoxic agents
were used in the two trials. Some in the field aim to
develop extensive tumour necrosis by the embol-
ization, while others use the embolic material to slow
down the blood flow to the tumour and not to
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permanently occlude the vessels and thereby permit
repeat procedures.
Local ablative therapies
As noted above, the definitive local therapy is surgical
resection, but newer ablative therapies, that aim to
ablate the lesion using a variety of technologies, are
now being widely used. The results achieved are
starting to challenge surgical resection.
Percutaneous alcohol injection
Ultrasound or CT-guided percutaneous injection of
sterile absolute alcohol into liver tumors, via a 19–22
gauge needle, under local anaesthetic consistently
induces vascular thrombosis and coagulative necrosis.
A total of between 2 and 100 ml of alcohol is injected
during the course of several sessions (depending on the
tumour size) and distributed as uniformly as possible
throughout the lesion. The most suitable patients are
those with less than three small (53 cm) tumours with
good underlying liver function (Child’s grade A). In
such patients complete response is obtained in around
80% with survival figures in the range of 3 and 5 years
in the order of 75% and 50%, respectively [24]. In such
patients it seems likely that results are at least as good as
surgical resection [25]. The benefits of PEI decrease
markedly in larger lesions; the procedure becomes
more tedious and it is more difficult to generate
complete necrosis, in part because of the presence of
septa within the lesion but also because of “run off” of
the alcohol into the vasculature. Most units will not
consider PEI for lesions 45 cm [26].
The procedure is cheap, simple to perform, does not
require a general anaesthetic and is virtually free of any
associated mortality. The only complications are
intense pain if the alcohol is allowed to leak out into the
peritoneal cavity, transient pyrexia, very occasional
episodes of haemoperitoneum (55% of cases) and,
very occasionally, tumour seeding along the needle
tract. Nonetheless, as with surgical resection, in 50–
70% of cases there will be intrahepatic recurrence. This
is particularly so in larger lesions and those that are
multifocal to begin with. Most will occur within 2 years
of the initial procedure [27,28].
How should one decide between surgical resection
and PEI in a patient with a solitary small liver tumour
before prospective randomized clinical trials directly
comparing the procedures are available? There are no
hard and fast rules and it is probably fair to say that
there is a trade-off between more early morbidity and
mortality with surgical resection and more late deaths
with PEI. If the patient is young, there are no co-
existing medical conditions and liver function is good,
most would still favour surgical resection. This has the
added theoretical benefit of removing surrounding
tissue that may be the site of micro-metastatic disease.
If there is any factor indicating significant operative
risk, co-morbidity, or the patient is elderly and frail,
then PEI is probably preferable. In the future it is likely
that the current position of PEI will be challenged by
radiofrequency ablation, largely on the grounds that
the lesions can be dealt with in a fewer number of
sessions.
Thermal and laser ablation
Both heating and cooling, locally administered under
ultrasound control, have been used to induce tumour
necrosis. “Cryotherapy”, which relies on a “freeze-
thaw” process is undoubtedly effective in delivering
local tumour control even in larger lesions (up to 8 cm)
but the probe needs to be large (up to 10 mm in
diameter) and the treatment needs to be delivered
under general anaesthetic [29]. The latter, in which
heat is developed from an alternating electric current in
the radiofrequency range, can result in complete
necrosis of a 3-cm tumour in 51 hour and in one
session. RFA is considered to be “minimally invasive”,
the needle electrodes being only 15-gauge. Depending
on tumour size and site it may be administered
percutaneously, intra-operatively or laparoscopically.
Some lesions, particularly those near to large vessels,
may be technically difficult to access.
Overall, the complication rate is510%, rather lower
than that reported for cryotherapy, as is the mortality.
Such opinions should be taken cautiously as the size of
tumour treated with RFA tends to be smaller than with
cryoablation and thus the inherent risks of the pro-
cedure are also smaller. Nonetheless there is a general
trend toward RFA and away from cryotherapy.
Moreover, the more rapid achievement of complete
tumour necrosis and easier access to tumour margins
has also led to a general trend towards RFA over PEI
[30–34]. Indeed, such is the enthusiasm for RFA that
prospective randomized trials comparing RFA with
surgical resection are currently underway.
Other technologies are being developed to achieve
similar ends to RFA and PEI and these include
photodynamic therapy and laser thermal ablation. The
latter has yielded encouraging results, and has the
advantage that it can be carried out under magnetic
resonance guidance, the whole procedure being
monitored with near real-time thermal imaging to
assess the efficacy of tissue necrosis [35,36].
Radiotherapy
The application of external beam irradiation for the
treatment of liver tumours has been severely limited by
the radiosensitivity of normal hepatocytes. Maximum
tolerance of normal liver to radiation is generally
accepted to be between 2500 and 3000 cGy; above this
level the risk of radiation hepatitis (veno-occlusive
disease with perivenular congestion and fibrosis)
increases rapidly [37].
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Internal irradiation with intra-arterial radioisotopes
Therapeutic doses of radioisotopes can be adminis-
tered into the hepatic artery using 90Y tagged to resin-
based or glass microspheres or 131I in conjunction with
lipiodol. Lipiodol-131I emits mainly g-radiation. The
volume of radioactive lipiodol administered is limited
by the size and vascularity of the tumour; thus in
practice, radioactive lipiodol is used only in patients
with tumours 55 cm in diameter [38]. About 40% of
patients will gain objective remissions with minimal
toxicities while keeping the radiation dose to a normal
liver below 2000 cGy. 90Y, a pure b-emitter, is more
powerful than 131I with a mean tissue penetration of
about 2.5 mm. Optimal tumour regression and re-
duction of serum AFP level are seen when the average
radiation dose to the tumour is 412 000 cGy. The
partial response rate is 450% [39]. Despite the pres-
ence of cirrhosis, there is little evidence of radiation
hepatitis, even when the non-tumorous liver receives
up to 7000 cGy. Leakage of the microspheres into
the right gastric artery or gastroduodenal artery may
occasionally cause radiation gastritis or duodenitis.
Systemic leakage of the microspheres to involve the
lungs, which are also sensitive to irradiation, may occur
if there is extensive arteriovenous shunting within the
tumour. For this reason, the degree of lung shunting
must be determined before administration of the
radioisotope by using a 99mTc macroaggregated albu-
min (99mTc-MAA) scan with g-camera scan [40].
Systemic chemotherapy
Almost all the cytotoxic agents used in oncologic
practice have been evaluated, and none has been
shown (as a single agent or in combination with other
agents) to improve survival or to achieve a consistent
response rate of420% [41–43]. The most widely used
agent has been adriamycin (doxorubicin). In a review
of several published trials involving4600 patients, the
objective response rate was 19% with a median survival
of 4 months. A reasonable approach is to administer
three courses and to reassess at 2 months. If there is
evidence of a response, in terms of a450% fall in serum
AFP or a decrease in liver or tumour size as determined
by ultrasound or CT scanning, then treatment should
be continued to a maximum dose of 550 mg/m2. Above
this cumulative dose, cardiotoxicity becomes increas-
ingly more frequent.
It is noteworthy that the most common primary liver
tumour in childhood, hepatoblastoma, is significantly
more chemosensitive (using various combinations of
cisplatin and doxorubicin), and it is now common
practice to administer chemotherapy before surgical
resection. Around 90% of cases will achieve remission,
and initially unresectable tumours can usually be
successfully resected or transplanted [44,45]. In a
similar manner, a regimen known as PIAF (platinum,
interferon, adriamycin, and 5-fluorouracil) has recently
been shown to convert about 10–20% of unresectable
adult HCCs to resectable ones, but this regimen
should remain experimental until controlled trials are
completed [46].
Hormonotherapy and biotherapy
There has been recent interest in altering the hormonal
environment of the tumours and small studies sug-
gested survival benefit from both anti-androgenic and
anti-oestrogenic agents. However, recent large-scale
prospective randomized controlled studies have failed
to find any support for these contentions [47–49].
A recent small prospective randomized study [50]
found significant improvement in survival for patients
receiving octreotide, a somatostatin analogue, but this
has not been subsequently confirmed [51].
Conclusions
Locoregional therapies and surgical resection, the de-
finitive locoregional treatment, are all capable of de-
livering complete local control in a percentage of cases,
the percentage decreasing as the tumour size increases.
It seems likely that all these would, in patients without
underlying liver disease, or with well compensated liver
disease, result in improvement in survival but this has,
to date, only been demonstrated in two small series of
patients receiving TACE. The treatment of choice will
depend on the ease and cost of the therapy, its com-
plication and acceptability rate and any benefit that can
be shown in prospective randomized clinical trials. The
problem with all these approaches remains the fact that
recurrence is the rule. What is needed therefore is
effective systemic therapy to supplement and enhance
the local control. To date this has not been demon-
strated but remains the long-term goal. However if, as
seems the case, therapeutic benefit can only be demon-
strated in patients with good underlying liver function
(Child’s grade A), and such patients will invariably
receive some form of locoregional therapy, there would
appear to be very little scope for testing novel systemic
therapies.
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